Glaxosmithkline Share News (GSK)

TOP NEWS: Haleon boosts annual guidance after solid first half

(Alliance News) - Haleon PLC on Wednesday upped its annual organic revenue growth guidance following a solid revenue performance in the first half of 2023.

IN BRIEF: GSK hails US FDA approval for cancer treatment, Jemperli

GSK PLC - London-based pharmaceutical company - Jemperli plus chemotherapy approved in the US by the Food & Drug Administration as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Notes Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy. Hesham Abdullah, senior vice president and global head of oncology development at GSK, says: "Today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

DIRECTOR DEALINGS: Qinetiq, Tesco and GSK executives sell shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced late last week and not separately reported by Alliance News:

LONDON BROKER RATINGS: Oddo BHF raises IAG to 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Q2 sales and earnings beat estimates

*

TOP NEWS: GSK raises annual guidance on quarterly earnings growth

(Alliance News) - GSK PLC on Wednesday upgraded its full-year guidance, after seeing a strong quarterly performance on the strength of segments like HIV and Vaccines.

GSK lifts full-year guidance after 'excellent' Q2

(Sharecast News) - GSK lifted its full-year guidance on Wednesday after an "excellent" second quarter.

GSK says HIV prevention drug recommended for marketing in Europe

(Alliance News) - GSK PLC on Monday said ViiV Healthcare's cabotegravir for HIV prevention has received a positive opinion by the European Medicines Agency for marketing authorisation.

GSK's ViiV gets Europe nod for HIV prophylaxis

(Sharecast News) - Pharmaceuticals giant GSK announced on Monday that its majority-owned HIV specialist subsidiary ViiV Healthcare has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorisation for 'cabotegravir' long-acting (LA) injectable and tablets for HIV prevention.

Bavarian Nordic ends RSV vaccine programme after poor trial results

July 22 (Reuters) - Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease.

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely

(Alliance News) - Stocks in London are expected to slip into the red at Friday's open, in a tepid conclusion to what has been a largely positive week for global equities, as the market prices in a lower peak for US interest rates.

Sensodyne toothpaste-maker Haleon planning job cuts - The Guardian

July 13 (Reuters) - Haleon, the world's biggest standalone consumer health business, is planning to cut hundreds of roles in the UK and worldwide, the Guardian reported on Thursday.

LONDON BROKER RATINGS: HSBC downgrades commercial property stocks

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

UK dividends calendar - next 7 days